ArticleBMC infectious diseases2025
Treatment outcomes for drug-resistant tuberculosis: a retrospective longitudinal study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond biomedical control: governance, social protection, and system gaps in tuberculosis control in Kazakhstan - a qualitative study of decision-makers.BMC public health · 2026Article
- Clinical characteristics, drug resistance profiles, and inflammatory cytokine signatures in newly treated versus retreated MDR/RR-TB patients: associations with treatment outcomes.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study examined the treatment outcomes of multidrug-resistant tuberculosis (MDR-TB) in Kazakhstan, where its burden is notably high.
methodsThe authors conducted a retrospective longitudinal study using the National Tuberculosis Registry, this study analyzed treatment outcomes in MDR-TB patients from 2018 to 2021, and included adult patients (≥ 18 years) who completed a specific treatment. Outcomes were categorized into successful and unsuccessful treatments. Bivariate and multivariate Poisson regression models with modified errors were employed to obtain crude and adjusted risk ratios (aRR).
resultsThe study cohort comprised 12,698 cases, of which 10, 306 (81.16%) completed treatment with a successful outcome, while 2,392 (18.84%) had unsuccessful outcomes. Male sex (aRR 1.35, 95% CI 1.24-1.45), urban residency (aRR 1.16, 95% 1.07-1.24), having both extrapulmonary and pulmonary tuberculosis (aRR 1.49, 95% 1.04-2.15), XDR-TB (aRR 1.31, 95% 1.08-1.59), excessive alcohol consumption (aRR 1.43, 95% 1.28-1.59), HIV-positive status (aRR 2.24, 95% 2.01-2.47), and drug abuse (aRR 1.37, 95% 1.10-1.71) significantly elevated the risk of the unsuccessful treatment.
conclusionOur findings underscore the need for focused strategies to reduce the MDR-TB burden, particularly among adults, male sex, relapsed cases, and XDR-TB. Despite the encouraging findings observed, further studies are necessary to update our estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.